NexImmune, Inc. NEXI
At closeNov 3, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 139
- EPS (ttm)
- -18.50
- Shares out
- 1.37M
- Forward P/E
- -0.30
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 100
- Avg volume
- 37
- Open
- 0.0002
- Previous close
- 0.0001
- Day's range
- 0.0002 – 0.0002
- 52-week range
- 0.0001 – 0.0003
- Beta
- 1.93
- Analysts
- Buy
- Earnings date
- Dec 27, 2024
2Y -0.2068 (-99.95%)
Key statistics
- Enterprise value
- -2.92M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.96M
- Total cash
- 4.45M
- Total debt
- 0
- Return on equity
- -196.47%
- Short % of float
- 1.30%
- 50-day average
- 2.33
- 200-day average
- 4.40
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 27, 2024
Expected Dec 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 27, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -1.69 | — | — |
| May 20, 2024 | Mar 1, 2024 | 0.00 | -2.21 | — | — |
| Apr 16, 2024 | Dec 1, 2023 | 0.00 | -4.99 | — | — |
| Nov 17, 2023 | Sep 1, 2023 | 0.00 | -9.40 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -7.25 | -7.25 | 0.00 | 0.00% |
About NexImmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- neximmune.com
News
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
12 Health Care Stocks Moving In Thursday's Intraday Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Friday's Intraday Session - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Your note
Sign in to keep a note on NEXI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARER SOL J | Director | Purchase | Mar 29, 2023 | 4,102,400 |
| BERTRAM TIMOTHY A | Director | Conversion of Exercise of derivative security | Feb 16, 2021 | 78,199 |
| CARMER SCOTT | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 16, 2021 | 7,058 |
| D'ANGIO PAUL | Director | Conversion of Exercise of derivative security | Feb 16, 2021 | 27,847 |
| JONES KRISTI VAUGHAN | Chief Executive Officer | Stock Award(Grant) | Nov 24, 2022 | 369,778 |
| OELKE MATHIAS | Officer | Stock Award(Grant) | Nov 21, 2022 | 134,023 |